Answers are grounded in this paper and cite their sources.
Randomized trial examines thymosin α1 for preventing severe COVID-19 in cancer patients, suggesting new therapeutic avenues.
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the 'COVID-19 vaccine race era' both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals.
No takes yet. Share an insight, caveat, or question.
Bersanelli et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: